DiaSorin S.p.A. (LON:0GZX)
London · Delayed Price · Currency is GBP · Price in EUR | Market Cap | 3.24B -28.4% |
| Revenue (ttm) | 1.02B -3.3% |
| Net Income | 123.66M -27.0% |
| EPS | 2.33 |
| Shares Out | n/a |
| PE Ratio | 26.19 |
| Forward PE | 17.62 |
| Dividend | 1.01 (1.43%) |
| Ex-Dividend Date | May 19, 2025 |
| Volume | 52,979 |
| Average Volume | 35,615 |
| Open | 68.58 |
| Previous Close | 68.28 |
| Day's Range | 68.30 - 70.66 |
| 52-Week Range | 51.14 - 97.40 |
| Beta | 0.66 |
| RSI | 70.52 |
| Earnings Date | May 7, 2026 |
About DiaSorin
DiaSorin S.p.A. engages in research and development, manufacture, and distribution of immunodiagnostics and molecular diagnostics testing kits in Europe, North America, and internationally. It provides various immunodiagnostic in the areas, including infectious diseases, gastrointestinal diseases, hepatitis and retroviruses, endocrinology, metabolic disorders, tumor markers, and oncology under LIAISON XL and LIAISON XS name. The company also offers Simplexa, a congenital CMV direct kit, which detects cytomegalovirus DNA in saliva swab and urine... [Read more]
Financial Performance
In 2025, DiaSorin's revenue was 1.20 billion, an increase of 0.81% compared to the previous year's 1.19 billion. Earnings were 155.62 million, a decrease of -17.27%.
Financial numbers in EUR Financial StatementsNews
DiaSorin price target lowered to EUR 62 from EUR 65 at Deutsche Bank
Deutsche Bank lowered the firm’s price target on DiaSorin (DSRLF) to EUR 62 from EUR 65 and keeps a Hold rating on the shares.
DiaSorin downgraded to Neutral from Buy at UBS
UBS analyst Kavya Deshpande downgraded DiaSorin (DSRLF) to Neutral from Buy with a price target of EUR 66, down from EUR 84. The firm sees modest risk to estimates and…
DiaSorin price target lowered to EUR 65 from EUR 74 at Deutsche Bank
Deutsche Bank analyst Jan Koch lowered the firm’s price target on DiaSorin (DSRLF) to EUR 65 from EUR 74 and keeps a Hold rating on the shares. Published first on…
DiaSorin price target lowered to EUR 60 from EUR 65 at Morgan Stanley
Morgan Stanley lowered the firm’s price target on DiaSorin (DSRLF) to EUR 60 from EUR 65 and keeps an Equal Weight rating on the shares.
DiaSorin price target raised to EUR 74 from EUR 71 at Deutsche Bank
Deutsche Bank analyst Jan Koch raised the firm’s price target on DiaSorin (DSRLF) to EUR 74 from EUR 71 and keeps a Hold rating on the shares. Published first on…
DiaSorin price target raised to EUR 65 from EUR 63 at Morgan Stanley
Morgan Stanley analyst Aisyah Noor raised the firm’s price target on DiaSorin (DSRLF) to EUR 65 from EUR 63 and keeps an Equal Weight rating on the shares. Published first…
DiaSorin upgraded to Neutral from Underperform at BNP Paribas
BNP Paribas analyst Hugo Solvet upgraded DiaSorin (DSRLF) to Neutral from Underperform.
DiaSorin downgraded to Equal Weight from Overweight at Morgan Stanley
Morgan Stanley downgraded DiaSorin (DSRLF) to Equal Weight from Overweight with a price target of EUR 63, down from EUR 99. The firm says macro headwinds continue to present earnings…
DiaSorin price target lowered to EUR 58 from EUR 68 at JPMorgan
JPMorgan lowered the firm’s price target on DiaSorin (DSRLF) to EUR 58 from EUR 68 and keeps an Underweight rating on the shares.
Italy's DiaSorin ex-Covid revenue in line with guidance
Italian medical diagnostics group DiaSorin on Friday reported a 3% rise in 2024 revenue, citing dampened demand for its products with a milder Flu season compared to the previous year.
Diagnostics group DiaSorin's nine-month adjusted core profit up 6%
Italian medical diagnostics group DiaSorin on Tuesday posted a 6% jump in nine-month adjusted core profit to 292 million euros ($318.46 million) at constant exchange rates, driven by its immunodiagnos...
Diasorin 2023 revenue drops 14%, in line with guidance; shares fall
Italian medical diagnostic group Diasorin on Friday reported a double-digit drop in revenue for 2023, in line with its revenue guidance for the year, but shares dropped as much as 7.3%.
Italy's DiaSorin sees 60% plunge in COVID-19 revenue next year
Italian diagnostics firm DiaSorin forecast weaker 2022 sales and a near 60% plunge in COVID-19 revenue, with the rapid rollout of vaccines likely to bring the pandemic under control and crimp demand f...
Italian biotech company DiaSorin says its Covid-19 tests can detect omicron variant
Carlo Rosa, CEO of DiaSorin, tells CNBC that the company's Covid-19 tests can detect the omicron variant and discusses what the impact of the new variant will be on mass testing.
The Vanguard Health Care Fund's Top 5 Trades of the 3rd Quarter
The Vanguard Health Care Fund (Trades, Portfolio) recently released its portfolio updates for the third quarter of 2021, which ended on Sept. 30.
Luminex Corporation Declares Second Quarter Cash Dividend
AUSTIN, Texas, May 20, 2021 /PRNewswire/ -- Luminex Corporation (Nasdaq:LMNX) (the "Company") today announced that its board of directors declared a cash dividend for the second quarter of 2021 of $0....
SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Luminex Corp. - LMNX
NEW YORK, April 16, 2021 /PRNewswire/ -- Juan Monteverde , founder and managing partner at Monteverde & Associates PC, a national securities firm rated Top 50 in the 2018 and 2019 ISS Securities Class...
LUMINEX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Luminex Corporation - LMNX
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Luminex Corporat...
INVESTIGATION ALERT: Halper Sadeh LLP Investigates LMNX, NUAN, CADE, GNMK; Shareholders are Encouraged to Contact the Firm
NEW YORK, April 13, 2021 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Luminex Corporation (NASDAQ: LMNX) concerning pote...
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Luminex Corporation
NEW YORK, April 12, 2021 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by Luminex Corporation (NASDAQ: LMNX) and its board of directors concerning the proposed a...
Italian Diagnostic Developer Calls Luminex a 'Perfect Fit'
Investors reacted favorably over the announcement that Saluggia, Italy-based DiaSorin SpA (MIL:DIA) is paying $1.8 billion to purchase Austin, Texas-based Luminex Corp. (NASDAQ:LMNX), a developer of p...
SHAREHOLDER ALERT: WeissLaw LLP Investigates Luminex Corporation
NEW YORK, April 12, 2021 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Luminex Corporation ("Luminex" or th...
Shareholder Alert: Ademi LLP investigates whether Luminex Corporation has obtained a Fair Price in its transaction with DiaSorin
MILWAUKEE, April 12, 2021 /PRNewswire/ -- Ademi LLP is investigating Luminex (NASDAQ: LMNX) for possible breaches of fiduciary duty and other violations of law in its transaction with DiaSorin. Click ...
DiaSorin to acquire Luminex Corporation for USD 37.00 per share or approximately USD 1.8 billion
SALUGGIA, Italy, April 11, 2021 /PRNewswire/ -- DiaSorin S.p.A. ("DiaSorin"; FTSE MIB: DIA) today announced that its Board of Directors has unanimously approved and signed a definitive merger agreemen...
Luminex Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of Luminex Corporation Is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – LMNX
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Luminex Corporation (NASDAQ: LMNX) to DiaSorin S.p.A. for $37.00 per share is fair ...